CMS proposes to keep Vivistim procedure payment rate at $45,000 for 2027

Mobia Medical, Inc. (Nasdaq: MOBI) announced that the Centers for Medicare and Medicaid Services (CMS) has proposed to maintain the Vivistim procedure under New Technology Ambulatory Payment Classification (APC) 1580 for calendar year 2027, with an associated hospital outpatient payment rate of approximately $45,000, unchanged from the 2026 rate.

The proposal applies to CPT Code 64568, the procedure code used for the Vivistim implant surgery. CMS is expected to publish the final Hospital Outpatient Prospective Payment System rule in November 2026, with any changes taking effect January 1, 2027.

"Continuity in reimbursement rates preserves stability for hospitals in order to confidently expand their Vivistim Programs and broaden access to our technology at their institutions for Medicare beneficiaries," said Richard Foust, President and Chief Executive Officer of Mobia.

The Vivistim Paired VNS System is an FDA-approved implantable device indicated to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. The device combines vagus nerve stimulation with functional movement therapy.

You May Also Be Interested In

• FDA grants accelerated approval to AstraZeneca's camizestrant combo
• Micropolis Robotics displays autonomous robots at Dubai investment event
• JPMorgan Reiterates Overweight Rating on Fortis Healthcare Ltd (FORH:IN)